PMID- 37693915
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230913
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 14
DP  - 2023
TI  - Phytochemicals targeting glycolysis in colorectal cancer therapy: effects and 
      mechanisms of action.
PG  - 1257450
LID - 10.3389/fphar.2023.1257450 [doi]
LID - 1257450
AB  - Colorectal cancer (CRC) is the third most common malignant tumor in the world, 
      and it is prone to recurrence and metastasis during treatment. Aerobic glycolysis 
      is one of the main characteristics of tumor cell metabolism in CRC. Tumor cells 
      rely on glycolysis to rapidly consume glucose and to obtain more lactate and 
      intermediate macromolecular products so as to maintain growth and proliferation. 
      The regulation of the CRC glycolysis pathway is closely associated with several 
      signal transduction pathways and transcription factors including 
      phosphatidylinositol 3-kinases/protein kinase B/mammalian target of rapamycin 
      (PI3K/AKT/mTOR), adenosine 5'-monophosphate (AMP)-activated protein kinase 
      (AMPK), hypoxia-inducible factor-1 (HIF-1), myc, and p53. Targeting the 
      glycolytic pathway has become one of the key research aspects in CRC therapy. 
      Many phytochemicals were shown to exert anti-CRC activity by targeting the 
      glycolytic pathway. Here, we review the effects and mechanisms of phytochemicals 
      on CRC glycolytic pathways, providing a new method of drug development.
CI  - Copyright (c) 2023 Zhan, Su, Li, Wen, Wei, He, Chen, Yin, Wang, Cai, Gong, Chen, Ma 
      and Zeng.
FAU - Zhan, Lu
AU  - Zhan L
AD  - Department of Oncology, Hospital of Chengdu University of Traditional Chinese 
      Medicine, Chengdu, China.
FAU - Su, Fangting
AU  - Su F
AD  - Department of Oncology, Hospital of Chengdu University of Traditional Chinese 
      Medicine, Chengdu, China.
FAU - Li, Qiang
AU  - Li Q
AD  - Department of Oncology, Hospital of Chengdu University of Traditional Chinese 
      Medicine, Chengdu, China.
FAU - Wen, Yueqiang
AU  - Wen Y
AD  - School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, 
      Chengdu, China.
FAU - Wei, Feng
AU  - Wei F
AD  - Department of Oncology, Hospital of Chengdu University of Traditional Chinese 
      Medicine, Chengdu, China.
FAU - He, Zhelin
AU  - He Z
AD  - Guang'an Hospital of Traditional Chinese Medicine, Guang'an, China.
FAU - Chen, Xiaoyan
AU  - Chen X
AD  - Guang'an Hospital of Traditional Chinese Medicine, Guang'an, China.
FAU - Yin, Xiang
AU  - Yin X
AD  - Guang'an Hospital of Traditional Chinese Medicine, Guang'an, China.
FAU - Wang, Jian
AU  - Wang J
AD  - Guang'an Hospital of Traditional Chinese Medicine, Guang'an, China.
FAU - Cai, Yilin
AU  - Cai Y
AD  - Department of Oncology, Hospital of Chengdu University of Traditional Chinese 
      Medicine, Chengdu, China.
FAU - Gong, Yuxia
AU  - Gong Y
AD  - Department of Oncology, Hospital of Chengdu University of Traditional Chinese 
      Medicine, Chengdu, China.
FAU - Chen, Yu
AU  - Chen Y
AD  - Department of Oncology, Hospital of Chengdu University of Traditional Chinese 
      Medicine, Chengdu, China.
FAU - Ma, Xiao
AU  - Ma X
AD  - State Key Laboratory of Southwestern Chinese Medicine Resources, School of 
      Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Zeng, Jinhao
AU  - Zeng J
AD  - Department of Gastroenterology, Hospital of Chengdu University of Traditional 
      Chinese Medicine, Chengdu, China.
AD  - TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of 
      Chengdu University of Traditional Chinese Medicine, Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230824
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC10484417
OTO - NOTNLM
OT  - colorectal cancer
OT  - glycolysis
OT  - molecular pathways
OT  - phytochemicals
OT  - warburg effect
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/09/11 06:42
MHDA- 2023/09/11 06:43
PMCR- 2023/08/24
CRDT- 2023/09/11 05:01
PHST- 2023/07/12 00:00 [received]
PHST- 2023/08/10 00:00 [accepted]
PHST- 2023/09/11 06:43 [medline]
PHST- 2023/09/11 06:42 [pubmed]
PHST- 2023/09/11 05:01 [entrez]
PHST- 2023/08/24 00:00 [pmc-release]
AID - 1257450 [pii]
AID - 10.3389/fphar.2023.1257450 [doi]
PST - epublish
SO  - Front Pharmacol. 2023 Aug 24;14:1257450. doi: 10.3389/fphar.2023.1257450. 
      eCollection 2023.